178 related articles for article (PubMed ID: 20059562)
1. Longer-acting factor VIII to overcome limitations in haemophilia management: the PEGylated liposomes formulation issue.
Di Minno G; Cerbone AM; Coppola A; Cimino E; Di Capua M; Pamparana F; Tufano A; Di Minno MN
Haemophilia; 2010 Jan; 16 Suppl 1():2-6. PubMed ID: 20059562
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A.
Spira J; Plyushch OP; Andreeva TA; Khametova RN
Thromb Haemost; 2008 Sep; 100(3):429-34. PubMed ID: 18766258
[TBL] [Abstract][Full Text] [Related]
3. Liposomal approach towards the development of a longer-acting factor VIII.
Powell JS
Haemophilia; 2007 Sep; 13 Suppl 2():23-8. PubMed ID: 17685920
[TBL] [Abstract][Full Text] [Related]
4. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.
Martinowitz U; Luboshitz J; Bashari D; Ravid B; Gorina E; Regan L; Stass H; Lubetsky A
Haemophilia; 2009 May; 15(3):676-85. PubMed ID: 19298381
[TBL] [Abstract][Full Text] [Related]
5. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study.
Spira J; Plyushch O; Zozulya N; Yatuv R; Dayan I; Bleicher A; Robinson M; Baru M
Haemophilia; 2010 Nov; 16(6):910-8. PubMed ID: 20491957
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study.
Powell J; Martinowitz U; Windyga J; Di Minno G; Hellmann A; Pabinger I; Maas Enriquez M; Schwartz L; Ingerslev J;
Thromb Haemost; 2012 Nov; 108(5):913-22. PubMed ID: 23014711
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
Rea C; Dunkerley A; Sørensen B; Rangarajan S
Haemophilia; 2009 Nov; 15(6):1237-42. PubMed ID: 19664015
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of haemostatic efficacy of plasma-derived FVIII by formulation with PEGylated liposomes.
Dayan I; Robinson M; Baru M
Haemophilia; 2009 Sep; 15(5):1006-13. PubMed ID: 19486171
[TBL] [Abstract][Full Text] [Related]
9. Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.
Epstein J; Xiong Y; Woo P; Li-McLeod J; Spotts G
Haemophilia; 2012 Mar; 18(2):187-92. PubMed ID: 21883704
[TBL] [Abstract][Full Text] [Related]
10. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
Shah A; Coyle T; Lalezari S; Fischer K; Kohlstaedde B; Delesen H; Radke S; Michaels LA
Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
Reipert BM; van Helden PM; Schwarz HP; Hausl C
Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients.
Brand B; Gruppo R; Wynn TT; Griskevicius L; Lopez Fernandez MF; Chapman M; Dvorak T; Pavlova BG; Abbuehl BE
Haemophilia; 2016 Jul; 22(4):e251-8. PubMed ID: 27328112
[TBL] [Abstract][Full Text] [Related]
13. Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis.
Miners AH; Krishnan S; Pasi KJ
J Thromb Haemost; 2016 Nov; 14(11):2141-2147. PubMed ID: 27510890
[TBL] [Abstract][Full Text] [Related]
14. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
Fischer K; Valentino L; Ljung R; Blanchette V
Haemophilia; 2008 Jul; 14 Suppl 3():196-201. PubMed ID: 18510542
[TBL] [Abstract][Full Text] [Related]
15. Forum on: the role of recombinant factor VIII in children with severe haemophilia A.
Franchini M; Coppola A; Molinari AC; Santoro C; Schinco P; Speciale V; Tagliaferri A
Haemophilia; 2009 Mar; 15(2):578-86. PubMed ID: 19187188
[TBL] [Abstract][Full Text] [Related]
16. New high-technology products for the treatment of haemophilia.
Pipe SW; Saint-Remy JM; Walsh CE
Haemophilia; 2004 Oct; 10 Suppl 4():55-63. PubMed ID: 15479373
[TBL] [Abstract][Full Text] [Related]
17. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
Lusher JM
Haematologica; 2000 Oct; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
[TBL] [Abstract][Full Text] [Related]
18. BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation.
Turecek PL; Bossard MJ; Graninger M; Gritsch H; Höllriegl W; Kaliwoda M; Matthiessen P; Mitterer A; Muchitsch EM; Purtscher M; Rottensteiner H; Schiviz A; Schrenk G; Siekmann J; Varadi K; Riley T; Ehrlich HJ; Schwarz HP; Scheiflinger F
Hamostaseologie; 2012; 32 Suppl 1():S29-38. PubMed ID: 22961422
[TBL] [Abstract][Full Text] [Related]
19. Prolonged effect of a new O-glycoPEGylated FVIII (N8-GP) in a murine saphenous vein bleeding model.
Pastoft AE; Ezban M; Tranholm M; Lykkesfeldt J; Lauritzen B
Haemophilia; 2013 Nov; 19(6):913-9. PubMed ID: 23730746
[TBL] [Abstract][Full Text] [Related]
20. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A.
Mullins ES; Stasyshyn O; Alvarez-Román MT; Osman D; Liesner R; Engl W; Sharkhawy M; Abbuehl BE
Haemophilia; 2017 Mar; 23(2):238-246. PubMed ID: 27891721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]